TAKEDA PHARMACEUTICAL CO LTD

TAK

Explore Our Financial Data > Companies > TAKEDA PHARMACEUTICAL CO LTD
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
TAK
CIK0001395064
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO, M0, 103-8668
Website takeda.com
Phone81332782111
CEOChristophe Weber
Employees47,300

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$30.56 billion
Pre-Tax Income$1.17 billion
Net Income$721.43 million
Net Income to Common$720.00 million
EPS$0.45
View All
Balance Sheet
Cash$2.57 billion
Assets$95.05 billion
Liabilities$48.78 billion
Common Equity$34.42 billion
Liabilities & Equity$95.05 billion
View All
Cash Flow Statement
Net Income$721.43 million
Cash From Operating Activities$7.05 billion
Cash From Investing Activities$-2.45 billion
Cash From Financing Activities$-5.01 billion
Change in Cash$-408.96 million
View All
Calculations
NOPAT$1.41 billion
EBITDA$7.34 billion
Price to Earnings$39.08
Price to Book$0.82
ROE1.53%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Hepatic Cirrhosis Market Research and Forecast Report 2026-2036, Profiles of Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion

The global hepatic cirrhosis market is expanding rapidly, fueled by increasing liver disease cases, advanced treatment options, and improved healthcare infrastructure. Conditions like hepatitis, alcohol abuse, and metabolic dysfunction-associated steatotic liver disease (MASLD) are elevating cirrhosis prevalence, especially in regions with factors like high alcohol consumption. Innovative treatments, including antiviral drugs and antifibrotic agents, are gaining traction, though challenges such

Article Link

Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year

KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company advances rinvatercept and elritercept studies.

Article Link

Takeda Pharmaceutical Q4 Earnings Call Highlights

Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around three expected product launches and a broader cost transformation program. The earnings call also mar

Article Link

Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers

Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted immune drug.

Article Link

Keros Therapeutics Reports Recent First Quarter 2026 Financial Results

LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today reported financial results for the quarter ended March 31, 2026. “Continuing to progress our pipeline remains

Article Link